title: Clinical profile of lean NIDDM in South India.
abstract: The majority (> 80%) of patients with non insulin dependent diabetes mellitus (NIDDM) present in Europe and America are obese. In developing countries like India, most NIDDM (> 60%) are non-obese and many are actually lean with a body mass index (BMI) of < 18.5 and are referred to as 'lean NIDDM'. This paper compares the clinical profile of a cohort of 347 lean NIDDM, with a group of 6274 NIDDM of ideal body weight (IBW) and 3252 obese NIDDM attending a diabetes centre at Madras in South India. The lean NIDDM who constituted 3.5% of all NIDDM patients seen at our centre, had more severe diabetes and an increased prevalence of retinopathy (both background and proliferative), nephropathy and neuropathy. Although a larger percentage of the lean NIDDM patients were treated with insulin, 47% of the males and 53% of the females were still on oral hypoglycaemic agents even after a mean duration of diabetes of 9.2 +/- 8.1 years. Studies of GAD antibodies, islet cell antibodies (ICA) and fasting and stimulated C-peptide estimations done in a small subgroup of the lean NIDDM showed that they were distinct from IDDM patients. More studies are needed on metabolic, hormonal and immunological profile of lean NIDDM seen in developing countries like India.
authors.affiliation: Madras Diabetes Research Foundation, India.
authors.forename: V
authors.initials: V
authors.lastname: Mohan
authors.forename: R
authors.initials: R
authors.lastname: Vijayaprabha
authors.forename: M
authors.initials: M
authors.lastname: Rema
authors.forename: G
authors.initials: G
authors.lastname: Premalatha
authors.forename: S
authors.initials: S
authors.lastname: Poongothai
authors.forename: R
authors.initials: R
authors.lastname: Deepa
authors.forename: E
authors.initials: E
authors.lastname: Bhatia
authors.forename: I R
authors.initials: IR
authors.lastname: Mackay
authors.forename: P
authors.initials: P
authors.lastname: Zimmet
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000276:immunology; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000502:physiology; D015992:Body Mass Index; D001835:Body Weight / Q000502:physiology; D002096:C-Peptide / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000453:epidemiology* / Q000503:physiopathology*; D003924:Diabetes Mellitus, Type 2 / Q000145:classification / Q000453:epidemiology* / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000503:physiopathology; D003971:Diastole; D004305:Dose-Response Relationship, Drug; D005215:Fasting; D005260:Female; D005968:Glutamate Decarboxylase / Q000276:immunology; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007194:India / Q000453:epidemiology; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000503:physiopathology; D017202:Myocardial Ischemia / Q000503:physiopathology; D009765:Obesity; D019518:Postprandial Period; D012907:Smoking; D013599:Systole; D014280:Triglycerides / Q000097:blood
chemical_list: D001323:Autoantibodies; D001786:Blood Glucose; D002096:C-Peptide; D002784:Cholesterol; D005968:Glutamate Decarboxylase; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D014280:Triglycerides